Evidence of Error

The journal articles listed below provide further insight into the existence of Specimen Provenance Complications (SPCs) in the diagnostic process. They also confirm the need for DNA Specimen Provenance Assay of positive biopsy results to prevent diagnostic mistakes resulting from SPCs. Each link provides access to full versions of the articles through PubMed.gov and various other online journals.

American Journal of Clinical Pathology—Occult SPCs in Routine Clinical Next-Gen Sequencing

Occult Specimen Contamination in Routine Clinical Next-Generation Sequencing Testing.
Jennifer K. Sehn, MD, David H. Spencer, MD, PhD, John D. Pfeifer, MD, PhD, Andrew J. Bredemeyer, PhD, Catherine E. Cottrell, PhD, Haley J. Abel, PhD and Eric J. Duncavage, MD. Occult Specimen Contamination in Routine Clinical Next-Generation Sequencing Testing. American Journal of Clinical Pathology. October 2015;144:667-674.

The Journal of Urology—Clinical and Economic Implications of SPCs

The Clinical and Economic Implications of Specimen Provenance Complications in Diagnostic Prostate Biopsies.
Wojno, K.; Hornberger, J.; Schellhammer, P.; Dai, M.; Morgan, T. The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies, The Journal of Urology. 2015 Apr;193(4):1170-7.

American Journal of Clinical Pathology—Rate of Occult SPCs

Rate of Occult Specimen Provenance Complications in Routine Clinical Practice
Pfeifer JD, Liu J. Rate of occult specimen provenance complications in routine clinical practice. American Journal of Clinical Pathology. 2013;139(1):93-100.

Value in Health—Provenance Testing of Biopsy Specimens

Development of a Decision-Analytic Model for the Application of STR-Based Provenance Testing of Transrectal Prostate Biopsy Specimens
Pfeifer JD, Singleton MN, Gregory MH, et al. Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens. Value in Health. 2012;15(6):860-867.

Journal of Clinical Oncology—Biopsy Misidentification Identified by DNA

Biopsy Misidentification Identified by DNA Profiling in a Large Multicenter Trial
Marberger M, McConnell JD. Fowler I, et al. Biopsy misidentification identified by DNA profiling in multicenter trial. Journal of Clinical Oncology. 2011; 29(13):1744-1749.

American Journal of Clinical Pathology—DNA-Based Specimen Provenance Testing

The Changing Spectrum of DNA-Based Specimen Provenance Testing in Surgical Pathology
Pfeifer JD, Zehnbauer B, Payton J. The changing spectrum of DNA-based specimen provenance testing in surgical pathology. American Journal of Clinical Pathology. 2011;135:132-138.

Pathology Case Reviews—Specimen Identity Testing Using DNA Analysis

Specimen Identity Testing Using Deoxyribonucleic Acid Analysis in Clinical and Surgical Pathology Setting

Harada S, Gocke C. Specimen identity testing using deoxyribonucleic acid analysis in clinical and surgical pathology setting. Pathology Case Reviews. 2010;15(4):116-120.

Journal of Urology—Patient Identification Error Among Biopsy Specimens

Patient Identification Error Among Prostate Needle Core Biopsy Specimens–Are We Ready for a DNA Time-Out?
Suba EJ, Pfeifer JD, Raab SS. Patient identification error among prostate needle core biopsy specimens–are we ready for a DNA time-out? Journal of Urology. 2007;178:1245-1248.  

CAP Today—With AP Specimen Identification

With AP Specimen Identification, the Hero Is Zero
Ford A. With AP specimen identification, the hero is zero. CAP Today. 2007.

Share this page on:
Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Share on LinkedInPrint this page